Quick Answer
STANDARD BIOTOOLS INC. reported Cash and Equivalents of $120.86 million for fiscal year 2025.
STANDARD BIOTOOLS INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $120.86M | -27.5% |
| 2024 | $166.73M | +222.5% |
| 2023 | $51.70M | -36.4% |
| 2022 | $81.31M | +185.8% |
| 2021 | $28.45M | -58.5% |
| 2020 | $68.52M | +216.3% |
| 2019 | $21.66M | -77.3% |
| 2018 | $95.40M | +64.3% |
| 2017 | $58.06M | +65.7% |
| 2016 | $35.05M | +20.4% |
| 2015 | $29.12M | -13.6% |
| 2014 | $33.71M | -4.4% |
| 2013 | $35.26M | -39.9% |
| 2012 | $58.65M | +332.7% |
| 2011 | $13.55M | +136.8% |
| 2010 | $5.72M | -60.8% |
| 2009 | $14.60M | -17.9% |
| 2008 | $17.80M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $129.42M | -38.6% | -18.4% |
| June 30, 2025 | $158.62M | -41.2% | +5.1% |
| March 31, 2025 | $150.88M | -47.4% | -9.5% |
| December 31, 2024 | $166.73M | +222.5% | -20.8% |
| September 30, 2024 | $210.65M | +164.4% | -21.9% |
| June 30, 2024 | $269.81M | +89.6% | -6.0% |
| March 31, 2024 | $287.06M | +152.6% | +455.2% |
| December 31, 2023 | $51.70M | -36.4% | -35.1% |
- STANDARD BIOTOOLS INC. showed a decrease of -27.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, STANDARD BIOTOOLS INC.’s cash and equivalents has grown by 579.2% (from $17.80 million to $120.86 million).
- The most recent figure is from STANDARD BIOTOOLS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: